SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 2347.
  • 2
    Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001; 6: 133146.
  • 3
    Mitsui I, Kumazawa E, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995; 86: 776782.
  • 4
    Kumazawa E, Jimbo T, Ochi Y, Tohgo A. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Pharmacol. 1998; 42: 210220.
  • 5
    Takiguchi S, Kumazawa E, Shimazoe T, Tohgo A, Kono A. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Jpn J Cancer Res. 1997; 88: 760769.
  • 6
    Rowinsky EK, Johnson TR, Geyer CE, et al. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a Phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol. 2000; 18: 31513163.
  • 7
    Royce ME, Hoff PM, Dumas P, et al. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J Clin Oncol. 2001; 19: 14931500.
  • 8
    De Jager R, Cheverton P, Tamanoi K, et al. DX-8951f: summary of Phase I clinical trials. Ann N Y Acad Sci. 2000; 922: 260273.
  • 9
    Daiichi Pharmaceutical Corporation. DX-8951f for injection. Investigators brochure (9th edition). Fort Lee, NJ: Daiichi Pharmaceutical Corporation, 1998: 922.
  • 10
    National Cancer Institute. Common toxicity criteria. Version 2.0. Bethesda: National Cancer Institute, 1998.
  • 11
    Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992; 10: 239253.
  • 12
    Oguma T, Ohshima Y, Nakaoka M. Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection. J Chromatogr B Biomed Sci Appl. 2000; 740: 237245.
  • 13
    D'Argenio DZ, Schumitzky A. ADAPT II user's guide. Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource, 1997.
  • 14
    Collins DG, Forrest A. IT2S user's guide. Buffalo: State University of New York at Buffalo, 1995.
  • 15
    Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 16
    Slichenmeyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993; 85: 271291.
  • 17
    Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol. 1988; 34: 755760.
  • 18
    Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989; 49: 14651469.
  • 19
    Kumazawa E, Tohgo A. Antitumor activity of DX-8951f: a new camptothecin derivative. Expert Opin Investig Drugs. 1998; 7: 625632.
  • 20
    Joto N, Ishii M, Minami M, Kuga H, Mitsui I, Tohgo A. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer. 1997; 72: 680686.
  • 21
    Lawrence RA, Izbicka E, de Jager RL, et al. Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells. Anticancer Drugs. 1999; 10: 655661.
  • 22
    Davidson K, Izbicka E, Lawrence C, et al. Anticancer activity of DX-8951f, a water soluble camptothecin against human tumor specimens taken directly from adult and pediatric patients [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 197a.
  • 23
    Boige V, Raymond E, Faivre S, et al. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. J Clin Oncol. 2000; 18: 39863992.
  • 24
    de Jager R, Cheverton P, Tamanoi K, et al. DX-8951f: summary of Phase I clinical trials. Ann N Y Acad Sci. 2000; 922: 260273.
  • 25
    Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352: 14131418.
  • 26
    Royce ME, Hoff PM, Dumas P, et al. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J Clin Oncol. 2001; 19: 14931500.
  • 27
    Giles FJ, Cortes JE, Thomas DA, et al. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res. 2002; 8: 21342141.
  • 28
    Perez EA, Hillman DW, Mailliard JA, et al. Randomized Phase II study of 2 schedules of irinotecan (CPT-11) for patients with refractory metastatic breast cancer: an NCCTG Cooperative Group study [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 206a.